Inhibikase raises $50 m at-the-market to fund Phase 3 IMPROVE-PAH trial

 

Inhibikase Therapeutics raises $50 million from RA Capital via at-the-market facility to fund Phase 3 IMPROVE-PAH trial

• Deal involves sale of 25 million common shares to RA Capital Management via at-the-market facility.
• Company expects proceeds to fund operations through topline Part B data from its Phase 3 IMPROVE-PAH trial.

https://finviz.com/stock?t=IKT&p=d